Indivior Sets Out Next Steps As It Braces For Suboxone Rivals
Indivior is exhausting all its options to try and stop the impending launch of US generic rivals to Suboxone from 19 February, including petitioning the country’s Supreme Court to intervene. But even if Dr Reddy’s and Alvogen do launch their versions next week, the originator is planning to combat them with an authorized generic.
You may also be interested in...
Mylan has joined Alvogen, Dr Reddy’s and Sandoz in the battle over US generic versions of Indivior’s Suboxone sublingual film. However, it is only marketing two of the four strengths offered by its rivals.
Alvogen and Dr Reddy’s have launched generic versions of Indivior’s Suboxone in the US, after the Supreme Court denied the originator’s attempt to further frustrate generic launches. But these two versions will compete with an authorized generic launched by Indivior through Sandoz.
Dr Reddy’s Laboratories is agonizingly close to resuming market activities for its generic Suboxone sublingual film product, but recently saw its case to have a mandate confirming the dismissal of a preliminary injunction turned down. In a market update, Suboxone manufacturer Indivior has outlined its plans to combat the imminent threat.